Preliminary Study on Eye Features of Patients With Malignant Tumors

Application of White Eye Imaging Health Care System on Diagnosis of Malignant Tumors

Based on the theory of traditional Chinese Medicine, this study collects eye features of white eyes through the White Eye Imaging Health Care System under visible light and establishes a database of eye-eye features corresponding to the disease. The computer image analysis and artificial intelligence technology are used to visualize the eye. The features were extracted and classified, and the corresponding changes in the characteristics of the traditional Chinese medicine and the disease were analyzed statistically to establish an analytical model corresponding to the disease.

Study Overview

• Status: Completed
• Conditions: Cancer Patients; Feature Elongation

Detailed Description

1. Collecting the white-eyed eye features of 500 patients with malignant tumors and 500 non-tumor patients by the white-eye shadowless imaging acquisition system under visible light, and establishing eye-catching images of malignant tumor patients and healthy people of different diseases. Feature database.
2. Based on the collected four-dimensional eye-eye diagram, using computer image analysis and artificial intelligence technology to extract and classify the eye-eye features of the white eye, and statistically analyze the correlation between the eye-eye features and the malignant tumor. The relationship between the characteristics of the white eye and the corresponding change of malignant tumor.

• Study Type: Observational
• Enrollment (Actual): 1000

Contacts and Locations

Study Locations

• China
  • Beijing, China, 100142
    • Yichen Dr. Xu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Participants in the study were patients with malignant tumors and healthy volunteers.

Description

Inclusion Criteria:

• Malignant tumor patients with clear pathological diagnosis;

  • Those who have no serious primary diseases of the cardiovascular, cerebrovascular, respiratory, endocrine, urinary, blood and other systems;

    • The main organs (hematopoiesis, heart, lung, liver, and kidney) have no obvious abnormal function; ④Age ≥18 years old, ≤75 years old; ⑤ No serious eye disease;

      • The patient volunteered to participate in this study.

Exclusion Criteria:

• Patients with severe blood loss (because when the bleeding exceeds 300ml, the white eye color of the patient is often pale white);

  • Poor patient compliance; ③ pregnant and lactating women;

    • Can't cooperate with inspection properly; ⑤ Cannot read or understand the scale.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Model of white-eye ocular features in patients with malignant tumors	The test will use Artificial Intelligence technology to analyze and learn the features of white-eye eyes of healthy people and patients with malignant tumors, and establish a model of eye characteristics of malignant tumors.	2.5 years

Collaborators and Investigators

• Sponsor: Peking University Cancer Hospital & Institute
• Investigators: Principal Investigator: Dong D Xue, Peking University Cancer Hospital & Institute

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2019
• Primary Completion (Actual): September 20, 2022
• Study Completion (Actual): September 20, 2022

Study Registration Dates

• First Submitted: January 8, 2020
• First Submitted That Met QC Criteria: January 8, 2020
• First Posted (Actual): January 13, 2020

Study Record Updates

• Last Update Posted (Actual): April 9, 2024
• Last Update Submitted That Met QC Criteria: April 6, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Cancer; Eye; Manifestations
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: WEIS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: This research is still in the exploratory stage and there are no plans to share IPD

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No